Ipratropium/Salbutamol Cipla (Salbutamol, Ipratropium Bromide Monohydrate)

Salbutamol activates β2‑adrenergic receptors on airway smooth muscle, stimulating adenylate cyclase and raising cyclic AMP levels. The increase in cyclic AMP leads to relaxation of the smooth muscle, opening the airways. In the combination, this effect is complemented by ipratropium’s anticholinergic action, resulting in additive bronchodilation.

The dosage of Ipratropium/Salbutamol is individualized and must be determined by a qualified healthcare professional. The prescriber will select the appropriate strength, frequency and duration based on the patient’s age, severity of disease and response to therapy. No generic dosing regimen is provided here.

Safety data for Ipratropium/Salbutamol in pregnancy and lactation are limited. The product should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant. Clinicians are advised to discuss the risk‑benefit profile with the patient and consider alternative treatments when appropriate.

To place an enquiry, visit the product page on gnhindia.com, enter the required quantity and submit the request. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

When delivered as a fixed‑dose combination, the two agents act synergistically, offering greater bronchodilation than either component alone. Using separate inhalers may require multiple devices and dosing steps, potentially reducing adherence. The combination simplifies administration while maintaining the pharmacologic benefits of both a β2‑agonist and an anticholinergic.

Ipratropium/Salbutamol should be stored at ambient temperature, preferably below 25 °C. Keep the inhalation device in its original packaging, protect it from moisture, direct sunlight and extreme temperatures. Do not expose the product to freezing conditions, and ensure the mouthpiece remains clean before each use.

The medication is delivered by inhalation, typically using a metered‑dose inhaler or a nebulizer as specified by the prescriber. The patient inhales the dose directly into the lungs, allowing rapid onset of action. Proper technique, including breath coordination and device cleaning, is essential for optimal therapeutic effect.

Serious adverse events include paradoxical bronchospasm, which worsens airway constriction after inhalation, and severe allergic reactions such as angioedema or anaphylaxis. Cardiovascular effects like arrhythmias may also occur, especially in patients with underlying heart disease. Prompt medical attention is required if any of these symptoms develop.

The combination is contraindicated in patients with a known hypersensitivity to salbutamol, ipratropium bromide or any excipients in the formulation. It should be used with caution in individuals with severe cardiac disorders, uncontrolled hypertension, or a history of paradoxical bronchospasm. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.